The ABCD audit programme was prominent at the recent EASD in Madrid with three presentations.
In a short oral presentation, Dr Emma Wilmot presented data showing that in the ABCD NHS England pilot audit of hybrid closed loop therapy (HCL) which was launched in 2021, irrespective of gender, ethnicity, age or socioeconomic status HCL is associated with similar reduction in HbA1c at 6-months.
In a short oral presentation, ABCD research fellow, Dr Alex Liarakos also presented an analysis from the ABCD NHS England pilot audit of hybrid closed loop therapy. The analysis demonstrated that HCL therapy is associated with long-term improvements in HbA1c, Time-In-Range, hypoglycaemia and diabetes-related distress in adults with type 1 diabetes in the real world.
In a short oral presentation, Dr Bob Ryder presented an analysis from the ABCD worldwide EndoBarrier registry which now has data on 1101 EndoBarrier treated patients. The analysis suggested that the considerable benefits of EndoBarrier on weight and HbA1c are achieved in 9‐months and a reduction in the recommended implantation period from 12‐ to 9‐months would reduce serious adverse events (SAE). In particular, over 60% of liver abscess SAEs would be avoided if the implantation period was reduced to 9-months.
